Skip to main content
. 2024 May 20;9:132. doi: 10.1038/s41392-024-01823-2

Table 7.

The clinically developed HGF/c-MET inhibitors

Type Drug Targets Highest phase Indications Identifier Status
Anti-c-MET mAbs Emibetuzumab(LY2875358) c-MET II Carcinoma, non-small-cell lung NCT01900652 Completed
II Advanced cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, hepatocellular cancer, renal cell carcinoma, non-small cell lung cancer NCT02082210 Completed
ABT-700 c-MET I Advanced solid tumors NCT01472016 Completed
Onartuzumab c-MET III Solid tumor NCT02488330 Completed
III Non-squamous non-small cell lung cancer NCT01456325 Completed
III Gastric cancer NCT01662869 Completed
III Non-squamous non-small cell lung cancer NCT01887886 Completed
III Non-small cell lung cancer NCT02031744 Completed
LY2875358 c-MET II Gastric cancer NCT01874938 Completed
II Non-small cell lung cancer NCT01897480 Active, not recruiting
II Non-small cell lung cancer NCT01900652 Completed
I/II Advanced cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, hepatocellular cancer, renal cell carcinoma, non-small cell lung cancer NCT02082210 Completed
Anti-HGF mAbs Rilotumumab HGF III Gastric cancer NCT02137343 Terminated
III Gastric cancer NCT01697072 Terminated
III Recurrent squamous cell lung carcinoma, stage IV squamous cell lung carcinoma NCT02926638 Terminated
II Recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma NCT01039207 Completed
Ficlatuzumab HGF II Resistant, recurrent or metastatic head/neck squamous cell carcinoma NCT03422536 Completed
II Non-small cell lung cancer NCT02318368 Terminated
YYB-101 HGF Ib/IIa Colorectal cancer NCT04368507 Completed
Nonselective TKI (ATP-competitive) Capmatinib c-MET IV Non-small cell lung carcinoma NCT05110196 Recruiting
Tepotinib c-MET II Non-small cell lung cancer NCT03940703 Active, not recruiting
II Solid tumor, MET exon 14 skipping mutation, MET amplification NCT04647838 Recruiting
II Advanced (Stage IIIB/IV) non-small cell lung cancer with MET exon 14 skipping alterations or MET amplification lung adenocarcinoma stage IIIB/IV NCT02864992 Active, not recruiting
II Colorectal neoplasms NCT04515394 Terminated
II Recurrent lung non-small cell carcinoma, stage IV lung cancer NCT06031688 Not yet recruiting
II Gastric cancer, gastroesophageal-junction cancer NCT05439993 Recruiting
I/II Advanced non-small cell lung cancer with MET mutations NCT04739358 Recruiting
I/II Non-small cell lung cancer NCT01982955 Completed
I/II Hepatocellular carcinoma NCT02115373 Completed
I/II Hepatocellular carcinoma NCT01988493 Completed
II

Breast cancer,

gastrointestinal cancer,

non-small cell lung cancer, other cancer

 NCT04591431 Active, not recruiting
AMG-337 c-MET II Stomach neoplasms NCT02016534 Terminated
II Solid tumor NCT03147976 Withdrawn
II Clear cell sarcoma NCT03132155 Terminated
I/II Stomach neoplasms NCT02096666 Completed
Nonselective TKI (allosteric) Tivantinib c-MET III Hepatocellular carcinoma NCT01755767 Completed
III Non-squamous, non-small cell lung cancer NCT01244191 Terminated
III Non-small cell lung cancer NCT01377376 Terminated
III Liver cancer NCT02029157 Completed
Nonselective TKI (ATP-competitive) Crizotinib c-MET, ALK, RON, AXL, TIE2, ROS1 IV Non-small cell lung cancer, anaplastic large-cell lymphoma, inflammatory myofibroblastic tumor NCT05160922 Recruiting
IV Anaplastic lymphoma kinase or ROS1-positive non-small cell lung cancer NCT03672643 Active, not recruiting
IV Systemic anaplastic large-cell lymphoma NCT02487316 Withdrawn
Cabozantinib c-MET, c-RET, VEGFR1-3, c-Kit, FLT-3, TIE2, TRKB, AXL IV Hepatocellular carcinoma NCT03963206 Completed
IV Medullary thyroid cancer NCT01896479 Active, not recruiting
Foretinib c-MET, VEGFR2, RON, ERK, AKT, PDGFRβ, c-Kit, TIE2 II Recurrent breast cancer NCT01147484 Completed
II Neoplasms, head and neck NCT00725764 Completed
II Carcinoma, renal cell NCT00726323 Completed
II Neoplasms, gastrointestinal tract NCT00725712 Completed
I/II Breast cancer NCT01138384 Completed
I/II Lung cancer NCT01068587 Completed
Glesatinib c-MET, AXL II Non-small cell lung cancer NCT02954991 Completed
Golvatinib c-MET, VEGFR2, RON, Eph, c-Kit I/II Advanced solid tumors NCT01433991 Terminated
I/II Platinum-resistant squamous cell carcinoma of the head and neck NCT01332266 Completed
Merestinib c-MET, MST1R, FLT-3, AXL, MERTK, TEK, ROS1, NTRK1/2/3, DDR1/2, MKNK1/2 II Carcinoma, non-small-cell lung, solid tumor NCT02920996 Active, not recruiting
II Biliary tract cancer, metastatic cancer, advanced cancer NCT02711553 Active, not recruiting

Source: All the information is derived from ClinicalTrials.gov (https://www.clinicaltrials.gov)